DOCETAXEL RETREATMENT IN DOCETAXEL-PRETREATED CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Di Lorenzo, Giuseppe [1 ]
Palmieri, Giovannella [1 ]
Buonerba, Carlo [1 ]
Marinelli, Alfredo [1 ]
De Placido, Sabino [1 ]
Altieri, Vincenzo [2 ]
Ferro, Matteo [2 ]
Mariano, Marsicano [2 ]
Vittorino, Montanaro [2 ]
Luigi, Castaldo [2 ]
Antonio, Tesone [2 ]
Modestino, Tronino [2 ]
机构：
[1] Univ Naples Federico 2, Dipartimento Endocrinol & Oncol Clin & Molecolare, I-80100 Naples, Italy
[2] Univ Naples Federico 2, Inst Urol, Dipartimento Scienze Ostetr Ginecolog Urolog & Me, I-80100 Naples, Italy
来源：
ANTICANCER RESEARCH | 2010年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
273
引用
收藏
页码：1533 / 1533
页数：1
相关论文
共 50 条
  • [41] Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
    Conteduca, Vincenza
    Jayaram, Anuradha
    Romero-Laorden, Nuria
    Wetterskog, Daniel
    Salvi, Samanta
    Gurioli, Giorgia
    Scarpi, Emanuela
    Castro, Elena
    Marin-Aguilera, Mercedes
    Lolli, Cristian
    Schepisi, Giuseppe
    Maugeri, Antonio
    Wingate, Anna
    Farolfi, Alberto
    Casadio, Valentina
    Medina, Ana
    Puente, Javier
    Mendez Vidal, Ma Jose
    Morales-Barrera, Rafael
    Villa-Guzman, Jose C.
    Hernando, Susana
    Rodriguez-Vida, Alejo
    Gonzalez-del-Alba, Aranzazu
    Mellado, Begona
    Gonzalez-Billalabeitia, Enrique
    Olmos, David
    Attard, Gerhardt
    De Giorgi, Ugo
    EUROPEAN UROLOGY, 2019, 75 (03) : 368 - 373
  • [42] Docetaxel versus docetaxel plus bevacizumab in progressive castration-resistant prostate cancer following first-line docetaxel
    Heidenreich, A.
    Pfister, D. J.
    Thueer, D.
    Brehmer, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer
    Guan, Wei
    Hu, Junhui
    Yang, Lu
    Tan, Ping
    Tang, Zhuang
    West, Brian L.
    Bollag, Gideon
    Xu, Hua
    Wu, Lily
    ENDOCRINE-RELATED CANCER, 2019, 26 (01) : 131 - 140
  • [44] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer
    Armstrong, A. J.
    George, D. J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2010, 13 (02) : 108 - 116
  • [46] Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer
    Brian Schurko
    William K Oh
    Nature Clinical Practice Oncology, 2008, 5 : 506 - 507
  • [47] Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer
    A J Armstrong
    D J George
    Prostate Cancer and Prostatic Diseases, 2010, 13 : 108 - 116
  • [48] Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer
    Schurko, Brian
    Oh, William K.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (09): : 506 - 507
  • [49] Treatment patterns in men with castration-resistant prostate cancer receiving docetaxel
    Davis, Keith L.
    Gutierrez, Benjamin
    Zyczynski, Teresa Maria
    Kaye, James A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
    Wilson, C.
    Scullin, P.
    Worthington, J.
    Seaton, A.
    Maxwell, P.
    O'Rourke, D.
    Johnston, P. G.
    McKeown, S. R.
    Wilson, R. H.
    O'Sullivan, J. M.
    Waugh, D. J. J.
    BRITISH JOURNAL OF CANCER, 2008, 99 (12) : 2054 - 2064
12345